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ABSTRACT 
BACKGROUND 
 Defective mucociliary clearance due to dehydration of airway surface liquid 
is proposed to be main reason for prolonged hospital stay and increased severity of 
symptoms in children with acute wheezing episodes due to viral infections. These 
episodes are most commonly due to Rhino viral infections. This study was 
undertaken to determine whether nebulization of 3% hypertonic saline with 
salbutamol decreases the hospital admission rate and clinical severity score in these 
children with acute wheezing episodes. 
 
METHODOLOGY 
 
This clinical trial was conducted in the casualty of INSTITUTE OF CHILD 
HEALTH   , EGMORE, from March 2014 to September 2014.In our study 114 
children between 2-6 years of age who presented to our hospital with acute 
wheezing episodes were included according to inclusion criteria. Out of 114 
children 14 children were excluded with exclusion criteria .Patient details were 
filled in standard proforma and asthma clinical scoring was done. These children 
alternatively had given normal saline with salbutamol and 3% hypertonic saline 
with salbutamol along with oxygen 3 times with 20 minutes interval. Post 
nebulization scoring and admission rate were noted. 
 
RESULTS 
 At the end of the study we found out of 29 (58%) children in 3% Hypertonic 
saline group have been admitted as against 41(82%) children in normal saline 
group with a p value of 0.009 which is significant. 22 (44%) children in 3% 
Hypertonic saline group had a clinical severity score of less than 6 and 28 (56%) 
children had clinical severity score of more than 6 with a p value of 0.010 which is 
significant. The risk difference in admission rate was 24% with a 95 % confidence 
interval of 6 to 40 %. 
DISCUSSION 
 
Clinical improvement caused by 3% hypertonic saline with salbutamol 
nebulization as evidenced by decrease in admission rate and improvement in 
asthma clinical severity score is in line with previous similar studies. 
 
 
 
 
CONCLUSION 
 
  3% hypertonic saline along with salbutamol has significantly reduced the hospital 
admission rate and clinical severity score in children with acute wheezing episodes 
due to viral infections. 
 
KEY WORDS---Acute wheezing-preschool children-airway surface liquid-
mucociliary clearance. 
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INTRODUCTION 
DEFINITION:
 
Wheeze is defined as a musical sound which is continuous and 
originates from oscillations in the narrowed airways. Wheezing is mostly 
heard during expiration due to critical narrowing of airways. 
 Polyphonic wheezing occurs due to widespread narrowing of 
airways that leads to various levels (or) pitches that is typically seen in 
bronchial asthma. Monophonic wheezing is usually produced in 
expiration and is single pitched. It occurs in conditions like 
Bronchomalacia and in distal tracheomalacia. Stridor is produced in 
inspiration and the obstruction is usually in extra thoracic airways. The 
airflow obstructions in airways are affected by the airway caliber and 
compliance of the lung. 
 
Airway resistance in the tube is inversely related to the radius of 
the tube to the fourth power. In most of the children aged less than 5 
years of age, the small diameter of the peripheral airways can lead to 50% 
of airway resistance. In these children an acute viral infection can lead to 
increased mucous secretion, inflammation and associated broncho 
constriction leading to acute wheezing episodes
1
.
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Bronchiolitis which occurs in children less than 2 years of age is 
due to respiratory syncytial virus. The increased severity of the 
respiratory syncytial virus during early infancy is due to presence of 
passively transferred maternal antibodies. The virus causes milder form 
of disease in older children.
2 
The viral induced upper and lower respiratory tract infections are 
the most common cause for acute wheezing episodes and admission in 
hospital and development of asthma in later age. The most common 
pathogens are Human rhino virus, Respiratory syncytial virus, Human 
meta pneumo virus (HMPV), .Human Para influenza virus (HPIV),Entero 
virus(EV), Influenza virus(INFV), Adeno viruses and Human Boca 
viruses. In the above viruses Human rhino virus, respiratory syncytial 
virus, Human Para influenza viruses are most commonly responsible for 
inducing acute wheezing episodes in children. These viruses were also 
responsible for exacerbation of asthma in children as well as in adults. In 
recent studies it was proved that respiratory syncytial virus is the most 
common virus that is responsible for 50% of acute wheezing episodes in 
infants.
2 
In recent studies it has been revealed that rhino viruses in the lower 
respiratory tract causes fluid and electrolyte movement across the luminal 
surface of the epithelial cells of the respiratory tract. These rhino viral 
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infections increase extra cellular adenosine tri phosphatase levels which 
leads to decrease in extra cellular adenosine tri phosphate levels (ATP). 
This decrease in adenosine tri phosphate levels leads to decrease in 
chloride secretion and increase in the levels of sodium absorption from 
airway surface liquid.  
Water is transported from airway surface liquid in to the mucosa 
along with electrolytes. This leads to dehydration of airway surface liquid 
and edema of sub mucosa and adventitia. These viral infections also 
cause increased mucous secretions and epithelial sloughing. They also 
lead to mucous plug formation. From above details it is clear that these 
viral infections by causing airway surface liquid dehydration causes 
failure of mucous clearance.
3 
AIRWAY SURFACE LIQUID
4 
The airway surface liquid is a thin layer of fluid, which covers the 
lumen of airways has a protective role of the airway epithelial cells from 
dehydration , inhaled particles, pathogenic organisms like bacteria’s and 
viruses.
 
The airway surface liquid has two layers:
 
1. Gel or mucous layer which floats over sol layer. 
 2. Watery peri ciliary or sol layer. 
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The exact volume and composition of these layers are still 
correctly not known. 
The airway surface liquid is regulated by ionic transport processes 
across airway epithelium. 
These two transport mechanisms are:
5 
1. Sodium absorption. 
2. Chloride secretion. 
So the proper function of airway surface liquid is necessary for the 
optimal function of mucociliary clearance, this in turn prevents retention 
of mucous and inhaled particles either organic or inorganic. Defective 
mucociliary clearances are the main predisposing factors for the 
pathogenesis of a number of chronic respiratory problems. There are 
number of therapies aimed at removing these accumulated mucous from 
airways. 
Chest physiotherapy is an example of physical removal of these 
retained secretions. It is highly effective, but expensive and time 
consuming. Pharmacotherapy which aims to enhance mucociliary 
clearance from airways includes mainly two agents, nebulized hypertonic 
saline, and nebulized mannitol. Inhalation of six percent hypertonic saline 
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with 10ml volume has dramatically improved symptoms of patients with 
cystic fibrosis.
 
Also the mannitol when given as aerosol from nebulizer improved 
the mucociliary clearance in cystic fibrosis patients and bronchiectasis. 
MECHANISM OF ACTION:
6,7,8 
Classification of muco active agents,
 
 Mucolytic 
 Expectorants 
 Mucokinetics 
 Ion transport modifiers 
 Other muco regulatory agents. 
As far as hypertonic saline is concerned it cannot be fitted into the 
group of muco active agents because of its multiple mechanisms of 
actions. Mucolytic agents disintegrate the structure of mucus and 
decrease its viscosity and elasticity. So the main aim of any mucolytic 
agent is to decrease the viscoelasticity of the airway secretions to 
facilitate their clearance from the airways.
9 
Even though hypertonic saline is not a mucolytic agent it is capable 
of disintegrating the ionic bonds within the mucous gel and decreasing 
cross linkage entanglements. Also hypertonic saline disintegrates the 
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DNA from the mucoprotein, which in turn allows the natural proteolytic 
enzymes to digest the mucoprotein.
10,11,12 
Hypertonic saline markedly increases the depth of liquid layer in 
the airway surface liquid by attaching to it. Hypertonic saline being an 
osmotic agent draws liquid into airway surface liquid from epithelial 
cells. Degree of restoration of the airway surface liquid varies depending 
upon the dose of hypertonic saline given locally as nebulization. The 
level of hypertonic saline reaches its high peak level temporarily and 
returns  close  to its pretreatment levels in about 10mts.Hypertonic saline 
also triggers cough , which improves cough mediated clearance by 
decreasing mucous adhesivity.
13 
Recently hypertonic saline appears to increase the levels of two 
thiols.
3 
 Glutathione 
 Thiocyanate 
Present in the airway surface liquid which has a protective effect 
against oxidation injury, which causes airway inflammation and release 
of neutrophils, eosinophil , mast cells, basophils and pro inflammatory 
mediators which in turn leads to edema, decreased mucociliary  
clearance, increased mucous production and chronic obstructive airway 
disease. 
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PRE SCOOL WHEEZING - ACUTE WHEEZING IN 2-6 
YEARS OLD 
There are several phenotypes involved in recurrent preschool 
wheezing and it has a variable prognoses and management. 
 Recurrent preschool wheezing is not synonymous with asthma 
because of its obvious relation to viral illness, temporal nature and lack of 
data on underlying inflammatory process. The degree of inflammation 
varies with different studies. 
In some studies neutrophils dominates and in some eosinophil’s, 
and in others no evidence of either. 
PHENOTYPES IN PRESCHOOL WHEEZING:- 
2 Major phenotypes involved. 
1. Virus induced wheezing. 
2. Multitrigger wheezing. 
VIRAL INDUCED WHEEZING:- 
It accounts for about two- thirds of all preschool wheezing. These 
phenotypes have normal premorbid lung function, intermittent airway 
obstruction and are asymptomatic between each episode. These children 
usually have a favorable prognosis. They only need   supportive 
treatment. 
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Respiratory syncytial virus can produce severe respiratory distress 
below 2 years of age and may lead to recurrent wheezing episodes in 
preschool children. Human Meta pneumovirus can also produce recurrent 
wheezing episodes. 
It has been proved that Rhinoviruses can trigger wheezing in early 
life and may lead to asthma in later life. 
MULTITRIGGER WHEEZING:- 
It is less common in early years of life, as it is usually caused by 
allergy. It manifests in preschool years of life. 
Family history of asthma and allergy is present with this 
phenotype.  It usually persists beyond early childhood. It is associated 
with significant deficits in lung function and growth up to 11 years of 
age.
14 
PATHOGENESIS
15 
OF VIRUS INDUCED 
WHEEZING 
After entry and replication the new viral particles are released and 
cause local and systemic infection. These viral particles recruits 
lymphocytes, monocytes, eosinophil’s, basophils and releases 
inflammatory mediators like IL-8 , cytokines, histamine, bradykinin and 
others. 
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These inflammatory mediators are responsible for broncho 
constriction, capillary leak, edema of airway, increased extra cellular 
ATP ase, stimulation of neural receptors responsible for broncho 
constriction leading to acute wheezing episodes. 
The increase in extra cellular ATP ase in the airway cells causes 
decrease in extra cellular ATP that leads to dehydration of airway surface 
liquid due to trans membranous transport of ions like sodium reabsorption 
chloride secretion. 
The dehydration of airway surface liquid along with broncho 
constriction due to release of inflammatory mediators leads to acute 
Wheezing attacks that often doesn’t respond to bronchodilators. 
CLINICAL FEATURES 
Affected children will develop malaise, headache, running nose, 
sneezing, conjuctival congestion, fever, cough, bronchospasms and acute 
wheezing episodes. 
COMPLICATIONS 
Complications due to rhino viral infections are uncommon. Most 
common complication is acute otitis media and exacerbation of chronic 
obstructive pulmonary disease.  
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INVESTIGATIONS 
1 .Antigen deduction 
2 .RT – PCR 
3 .Restriction fragment length polymorphism 
4. Compliment fixation  
5. Haem agglutination inhibition 
6. Enzyme linked immuno assay  
TREATMENT:- 
Conservative management includes bed rest, hot liquids, anti- 
pyretics  and antihistamines . 
Specific management: 
 1.PLECONARIL 
 2.INTERFERON-GAMMA 
 Above these two agents are not used because of their side effects. 
 3.ZINC : It binds to small crevice on the outer aspect of virus 
known as binding pockets. This also acts as a binding site of ICAM1. 
Thus preventing conformational changes in the capsid of virus due to 
stimulation of ICAM 1 .But it is not used for routine prophylaxis of rhino 
viral infection.  
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Introduction of zinc at any point of infection will prevent 
replication and propagation of infection. 
 EUROPEAN RESPIRATORY SOCIETY TASK FORCE 
APPROACH TO PRESCHOOL WHEEZING:-
16 
1. Preschool wheezing is classified in to episodic (viral) induced 
wheezing or Multitrigger wheezing. 
2. The terms used, such as transient, late onset and persistent wheeze 
should be limited to population – based cohort studies only. 
3. In preschool wheezing the term ―ASTHMA‖ should not be used 
because of lack of evidence of underlying inflammation. 
APPROACH TO THE ASSASSMENT OF PRESCHOOL 
WHEEZING BY EUROPEAN RESEARCH SOCIETY:- 
1. In history taking personal history, family history of allergies, 
pattern and trigger of wheeze and house hold smoking should be 
assessed. 
2. In children requiring long term management allergy testing should 
be performed. 
3. Health care professional should verify when a parent reports with 
wheezing in their child. 
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4. Further investigations are needed only in severe, therapy resistant 
or wheezing associated with clinical features. 
PHARMACOLOGICAL THERAPY
17 
For the prevention of symptoms and improvement of long term 
outcome of preschool wheezing, along with allergen avoidance, parent 
education, environmental control and pharmacological treatment plays an 
important role. 
ACUTE MANAGEMENT:-
18 
Acute preschool wheezing symptoms are treated with 
1. Oxygen 
2. Short acting beta-agonists 
3. Systemic corticosteroids( prednisolone) 
In mild to moderate wheezing due to viral infections oral 
prednisolone has not been much useful. 
The usefulness of ipratropium bromide is minimal. It may have 
additional effect to short acting beta-agonists, particularly in infants. 
PREVENTIVE TREATMENT:- 
INHALATION CORTICOSTEROIDS:-
19,20
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In young children with recurrent wheezing, inhalational 
corticosteroids only have limited long term effectiveness. It has some 
short term effectiveness but clear disease modifying effect was never 
seen. 
LEUKOTRIENE RECEPTOR ANTAGONIST 
(MONTELEUKAST):-
21,22,23,24 
 It is more useful to prevent virus induced wheezing attacks. Its 
clinical effect is more likely that of low dose inhalational corticosteroids. 
LONG ACTING BETA AGONISTS (LABA):- 
Long acting Beta agonists are not recommended in preschool 
children. 
NEBULIZER
25 
A Nebulizer is a device which changes liquid medication into a 
mist which can be easily inhaled into the respiratory system for the 
delivery of aerosolized drugs. 
AEROSOL DEPOSITION:
26 
The efficacy of an aerosol as a vehicle for delivering drugs in to the 
lower airways depends mainly on droplet or particle size. Smaller 
particles have greater chance of peripheral penetration and retention. 
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The particles with size of more than 10micro meter in diameter are 
most likely to deposit in the mouth and throat. Particles with size between 
5 to 10 micrometers in diameter are deposited in upper airways. 
Particles with size less than 5 micrometer in diameter are deposited 
frequently in the lower airways which are most appropriate for 
pharmaceutical aerosols. 
PARTS OF A NEBULIZER:
27
   
1. Compressed air machine. 
2. Medication cup for the medication. 
3. A thin plastic tube which connects the medication cup to the 
compressed air machine. 
4. A face mask that helps to breath in the mist. 
TYPES OF NEBULIZERS:
27 
MECHANICAL NEBULIZER: 
1. HOME MADE:- 
Mechanical nebulizers are made at home with a help of a sealed 
bottle with cork using volatile liquid such as alcohol and a ball inflating 
needle connected to a bicycle pump. 
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The bottle is closed with a cork and a hole is made in the cork with 
a drill. A ball inflating needle is inserted in to the cork and connected to a 
bicycle pump.  
With the help of bicycle pump the pressure inside the bottle is 
increased and the cork is suddenly removed. This rapid change in air 
pressure will vaporize the liquid in to a mist. 
SOFT MIST INHALER:- 
It was invented by ―Boehringer Ingelheim‖ medical company in 
1997. This inhaler has a spring at the bottom of the liquid container. 
When the user rotates the bottom of the inhaler to 180
0 
 the spring in the 
bottom is activated and releases energy and causes the liquid to spray out 
of two nozzles leading to soft mist formation. 
This device does not use any gas propellant or power source. But 
the droplet size produced in this technique was 5 to 8 micrometers. This 
may interfere with the delivery of aerosol in to the lower respiratory 
system. 
HUMAN POWERED NEBULIZER:- 
It was invented in ―Maquette university‖ in 2009. It is useful in 
areas of limited electricity. This technique uses bicycle frame and pedals 
which are connected to a piston that turns the liquid in to a mist.  
16 
 
ELECTRICAL NEBULIZERS:
28,29 
1. Jet nebulizers. 
2. Vibrating mesh nebulizers. 
3. Ultrasonic wave Nebulizers. 
JET NEBULIZERS:- 
These are most commonly used liquid nebulizers. They are also 
called as ―atomizers‖. 
 Jet nebulizers works on the basis of VENTURI PRINCIPLE. 
Jet nebulizers use a compressor which makes the liquid medicine 
in to an aerosol, by driving the compressed air or oxygen to flow at high 
velocity in to the liquid medicine. 
ADVANTAGES: 
1. Easy to use. 
2. Requires simple tidal breathing. 
3. Dose modifications are possible. 
4. Dose compounding is also possible. 
5. Works at low operational cost. 
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DISADVANTAGES:- 
1. Cost of the air compressor. 
2. Need for an external power source. 
3. Contamination is possible if not cleaned properly after use. 
4. They generate more noise (60 db). 
5. Less portable due to heavy weight. 
Design modifications in jet nebulizers lead to production two new jet 
nebulizers,  
1. Pari LC plus 
2. Dosimetric aeroeclipse. 
They act through breath enhanced and act as open vent nebulizers. 
Now a day’s several manufacturers reduced the weight of the jet 
nebulizers to 635 grams and made it in to a portable device. 
VIBRATING MESH NEBULIZERS:-
30 
Ultrasonic vibrating mesh technology (VMT) was invented in 
2005. 
In this technique a mesh with 1000-7000 holes driven by laser 
vibrates at the top of reservoir and produces very fine mist of these 
droplets through the holes. 
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Available mesh (VMT) nebulizers are: 
1. Respironics i- nebulizer 
2. Omron micro air 
3. Pari eflow 
4. Beurer nebulizer IH 50 
5.  Aerogen Aeroneb 
ADVANTAGES:- 
1. Shortened treatment time. 
2. Does not produce undesired heating. 
3. Has not produced much liquid waste at the end of nebulization. 
4. Portable, useful during travelling. 
DISADVANTAGES:- 
1. Battery (powered) operated. 
2. Should be cleaned regularly, to prevent blockage. 
3. High cost of the instrument. 
ULTRASONIC WAVE NEBULIZER:- 
It is a new portable nebulizer which was invented in 1964. 
In this nebulizer high frequency ultrasonic waves are produced by 
electronic oscillator that creates mechanical vibration of piezoelectric 
element. 
19 
 
This vibration converts the liquid in the chamber into a mist. The 
weight of this machine is only around 170 grams. 
ADVANTAGES:- 
1. Noise reduction. 
2. Portable, compact. 
3. Less weight. 
4. Do not require saline for aerosol formation. 
5. Fast acting. 
DISADVANTAGES:- 
1. Expensive. 
2. Fragile. 
3. May cause drug degradation. 
4. Do not nebulize suspensions well. 
EXAMPLES OF ULTRASONIC NEBULIZERS:- 
1. Beurer Nebulizer IH 30. 
2. Omron NE- U 17. 
PROPER NEBULIZATION TECHNIQUE:-
31 
1. The liquid medication that is used for nebulization should not be 
out of date. 
2. It should be properly stored. 
20 
 
3. The nebulizer machine should be properly working. 
4. A minimum of 2 to 3ml of liquid medication is needed to produce 
required amount of mist. 
5. If we use more volume of liquid medication the duration of 
nebulization time will also be prolonged. 
6. The more volume of liquid medication we use initially to nebulizer 
the more amount of drug will be delivered to the patient. 
7. In Jet Nebulizers there will be some residual volume of drug at the 
end of nebulization. 
8. Drug wastage can be minimized by using a volume of at least 4ml 
of nebulizer solution within 10 minutes time using flow rates of 8 
lit/min. 
9. The dead volume can be further minimized by tapping the 
nebulization chamber during nebulization. 
10. Before starting Nebulization make the child relaxed as much as 
possible. And make the child be occupied in some activities like 
reading or watching something interesting. 
11. For young children parents will have to be involved more during 
nebulization. 
12. For older children before giving nebulization they can be told how 
to hold nebulization chamber during nebulization procedure. 
21 
 
13. A crying child cannot have effective nebulization. So child can be 
nebulized during sleep with the help of a face mask. 
14. Young infants and toddlers can be nebulized with the help of face 
mask. Older children can be nebulized with the help of mouth 
piece connected to a nebulizer machine. 
15. Older children can be educated to take slow and deep inhalations 
and occasional short rests with every 30 seconds. 
16. A Nose clip can be used to occlude the nose to make sure that the 
inhalation takes place through the mouth than nose. It can be used 
in older children not in young infants as it may lead to more 
agitation in younger children. 
17. The duration of nebulization time is between 5 to 15 minutes. It 
depends on the nebulizer type used, rate, depth of respiration, 
initial volume of medication used for nebulization and the 
cooperation of the child. 
18. In most cases the majority of drug is delivered during first 5 
minutes. By extending beyond 10 minutes little more volume of 
drug can be delivered to the patient. 
19. Sputtering noise of nebulizer bowel signifies that the nebulization 
procedure is complete and no further mist or medication will be 
delivered after this time. 
22 
 
MAINTANENCE OF A NEBULIZER:- 
CONTROL OF CONTAMINATION:- 
 Nebulizers should be rinsed and air dried between each use to 
prevent clogging of Venturi mask and to avoid contamination 
with microorganisms. 
  Nebulizers should be disinfected by soaking once or twice in a 
weak with an acetic acid solution for 30 minutes (1 part of 
distilled vinegar mixed with 3 parts of warm water). 
 It can be also disinfected with a quarternary ammonium 
compound for about 10 minutes. Finally nebulizers should be 
rinsed with tap water. 
 Compressor filter and nebulizer should be replaced every 6 
months. 
CONTROL OF ALLERGENS:- 
 The allergens such as cat, dog, mouse and cockroaches can 
contaminate the reservoir of nebulizers. 
 Proper storage and cleaning of nebulizer will prevent it from 
contaminating with allergens. 
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DETERIORATION OF FUNCTION:- 
 With repeated use of nebulizers, its performance deteriorates with 
time. Proper usage and maintenance of nebulizers will slow down the 
deterioration time. 
 The replacement time for each nebulizer depends on the 
manufacturer’s recommendation but it should not exceed 6 months. 
DRUGS THAT CAN BE DELIVERED THROUGH 
NEBULIZATION. 
1. Salbutamol   
2. Corticosteroids,  
3. Ipratropium,  
4. Adrenaline, 
5. Hypertonic saline  
6. Normal saline  
Can be delivered through nebulizers. Drugs are available as respules or 
vials. When vials are used drugs should   be diluted with saline and not 
with plain water. 
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POTENTIAL HAZARDS OF NEBULIZATION:- 
Salbutamol Nebulization without oxygen in a sick child with 
wheeze can cause preferential bronchodilatation resulting in ventilation 
perfusion mismatch and leads to deterioration in clinical condition of the 
child. Hence nebulization should always have to be given with oxygen in 
a sick child. 
An alternative to using Jet nebulizer is connecting nebulization 
chamber to oxygen humidifier and using oxygen driven nebulization. 
Oxygen delivered at rates of 8-10 liters / minute break the drug solution 
into mist and results in effective nebulization. 
VARIOUS SCORING SYSTEMS USED FOR THE 
ASSESSMENT OF RESPIRATORY DISTRESS: 
 
1. Wang’s scoring system 
2. Respiratory distress assessment instrument 
3. Asthma clinical severity scoring 
 
PARAMETERS USED IN WANG”S SCORING SYSTEM 
  1. Respiratory rate 
  2. Oxygen saturation 
  3. Capillary refill time 
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    4. Chest retractions 
  5. Air entry 
  6. Level of consciousness 
   
PARAMETERS USED IN RESPIRATORY DISTRESS 
ASSESSMENT INSTRUMENT 
 
1. Wheezing(inspiratory,expiratory) 
 
2. Location 
 
3. Retractions( supra clavicular, infra clavicular,sub costal) 
 
4 .Respiratory rate 
 
PARAMETERS USED IN ASTHMA CLINICAL 
SEVERITY SCORE 
1. Respiratory rate   
 A.2 to 3 years  
 B.4 to 6 years 
2.  Oxygen saturation in room air 
3.  Auscultation 
4.  Retractions 
5. Dyspnea. 
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WANG”S SCORING SYSTEM 
  
Respiratory 
Rate 
0 – 
NORMAL 
1 – MILD 2 – MODERATE 3 - SEVERE 
      < 40 40-50        50-60 >60 
Color 
O2 
Saturation 
on room air 
Cap Refill 
Normal 
>97% 
<2 sec 
Normal 
94-96%  
on Room 
air < 2 sec 
Normal 
90-93% 
< 2 sec 
Normal color on 
02 < 1 lpm 
Dusky, Mottled 
< 90% 
=> 3 sec 
Normal color 
on 02 
> 1 lpm 
Retractions   
/ WOB 
None 
Sub costal 
retractions 
Inter costal and 
Sub costal 
retractions when 
Quiet 
Supra 
clavicular 
Sternal 
retractions 
Paradoxical 
Respiration 
Air Entry 
Wheezing 
Breath Sounds 
Clear / Good 
Good Entry 
End 
Expiratory 
Wheeze 
+/- Rales 
Fair Air Entry 
Inspiratory and 
Expiratory 
Wheeze +/- Rales 
Poor / Grunting 
Inspiratory and 
Expiratory 
Wheeze 
+/- Rales 
LOC Normal /Alert 
Mild 
Irritability 
Restless when 
Disturbed- 
Agitated 
Lethargic Hard 
to Arouse 
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RESPIRATORY DISTRESS ASSESSMENT INSTRUMENT 
Respiratory Distress Assessment Instrument 
Wheezing 0 1 2 3 4 
Expiration None End 1/2 3/4 All 
Inspiration None Part All   
Location None 
Segmental 
<2 of 4 
lung fields 
Diffuse > 3 
of 4 lung 
fields 
  
Retractions      
Supra Clavicular None Mild Moderate Marked  
Inter costal None Mild Moderate Marked  
Sub costal None Mild Moderate Marked  
Respiratory Rate      
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 ASTHMA CLINICAL SEVERITY SCORE 
Respiratory Rate 1 Point 2 Point 3 Point 
2-3 Years < 34 35-39 > 40 
4-6 Years < 30 31-35 > 36 
Oxygen Saturation 
in room air 
> 95 90-95 < 90 
Auscultation 
Normal or End 
Expiratory 
wheezing 
Expiratory 
wheezing 
Inspiratory & 
Expiratory 
wheezing / 
decreased breath 
sounds or both 
Retractions 
None / 
Intercostal 
retractions 
Inter costal & 
Sub sternal 
retractions 
Inter costal / Sub 
costal & 
Supraclavicular 
retractions 
Dyspnea 
Speaks in 
sentences 
Speaks in short 
sentences 
Speaks in single 
words / Grunts 
CS Score 5-7 (Mild) 8-11 (Moderate) 12-15 (Severe) 
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REVIEW OF LITERATURE 
Dorit ater et al, conducted a study on hypertonic saline with 
albuterol in preschool children with acute wheezing episodes. It was a 
prospective randomized double blind study. In this study children aged 
between 1 to 6 years attending emergency department are evaluated for 
the efficacy of 5% hypertonic saline with albuterol was compared with 
0.9 % normal saline with 0.5ml albuterol. The sample size was 41. These 
children after randomization given 1 dose of albuterol inhalation. Then 
they are given 4ml of 5% hypertonic saline with 0.5ml of albuterol or 4ml 
of 0.9% normal saline with 0.5 ml of albuterol 2 doses with 20 minutes 
interval four times a day. 
In this study the primary outcome measured was length of hospital 
stay. The secondary outcome measured was clinical severity score and 
admission rate. In 5% hypertonic saline group 16 children were involved 
and in 0.9% normal saline group 25 children were involved. In this study 
length of stay was significantly lower in hypertonic saline group than 
normal saline group. Median 2 days (range 0 to 6) against 3 days (range 0 
to 5) days. P value was 0.027. 
Admission rate was significantly lower in hypertonic saline group 
in comparison with normal saline group. The admission rate was 62.2% 
in hypertonic saline group, against 92% in normal saline group. The 
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clinical severity score significantly improved in both groups. But there is 
no significant correlation between them.
3 
Mark R Elkins et al conducted a study of mechanism of action of 
hypertonic saline in cystic fibrosis patients. They found out that 
inhalation of various concentration of hypertonic saline increased the 
ability of the patients to expectorate the mucous from the respiratory 
tract.
4 
Reider and Colleagues conducted a cross sectional study in 
persons with cystic fibrosis disease exacerbation. In this study persons are 
divided in to two groups: normal saline group and hypertonic saline (6%) 
group. Prior to the physiotherapy they were given nebulization with 0.9% 
and 6% hypertonic saline and 1 hour after sputum was collected from 
these patients after physiotherapy. Sputum expectoration was more in 
hypertonic saline group than in normal saline group.
32 
E. Michael sarrel and Colleagues conducted a study in 
ambulatory children with viral bronchiolitis with 3% hypertonic saline 
nebulization. They had found out that 3% hypertonic saline along with 
terbutaline has effectively decreased the symptoms of bronchiolitis in 
these children.
33 
Avigdor Mandelberg and Colleagues conducted a study in infants with 
viral bronchiolitis with Epinephrine 1.5mg and 4ml of 0.9 % saline or 3% 
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hypertonic saline. They found out that 3% hypertonic saline along with 
1.5mg of epinephrine inhalation had decreased the signs and symptoms in 
comparison with 0.9% saline along with 1.5mg of epinephrine.
34 
Suri et al conducted a study on the effect of hypertonic saline and 
durnase – alpha on the inflammatory mediators in cystic fibrosis. They 
have found out that after 3% hypertonic saline inhalation, the Interleukin 
levels are significantly reduced
35
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E.Daviskas et al, conducted a study on the effect hypertonic saline 
inhalation in mucociliary clearance of both normal and asthmatic people. 
In this study 10 healthy individuals and 12 asthmatic subjects were 
involved. To these subjects ultrasonically nebulized 0.9% saline, 
ultrasonically nebulized 14.4% saline and a control to which no aerosol is 
added, given at three separate days.
99m
TC _ sulphur colloid, computer 
analysis and Gamma camera were used for measuring mucociliary 
clearance. 
 The asthmatic persons were given 2.2 1.2ml mean  SD volume 
of 14.4% saline. And the healthy subjects received 3.2  0.7ml of 14.4% 
saline. The time taken for the delivery of this volume of saline was 5.4  
1.3 min and 6.4  0.7 min for asthmatic subjects and healthy subjects.  
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The effect of 14.4% saline on the airway was measured with the 
help of fall in forced expiratory volume in one second which was 
measured separately on the next visit. The FEV1   for asthmatic subjects 
was 22  4% and 3  2.1% for healthy subjects. 
 While comparing the mucociliary clearance of control and 0.9% 
saline, the hypertonic saline group has increased mucociliary clearance. 
With this results they concluded that inhalation of hypertonic saline 
increases mucociliary clearances in both asthmatic and normal subjects. 
PG.Middleton et al, studied the effect of hypertonic saline on the 
transport of ions across the airway epithelium. In this study 7 nonsmoking 
subjects were chosen for the study. It was ensured that they had not under 
gone any surgery within 4 weeks or had any respiratory tract infection. 
They are given hypertonic saline nebulization and mannitol nebulization. 
Then the nasal potential difference measured by passage of small 
exploring electrode through the floor of the nose. 
 The value of 1m mannitol is some like that of 500mm of sodium 
chloride. By this study they concluded that the human respiratory 
epithelium responds independently to the altered osmolarity
5
. 
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 Jasmijn teunissen et al, studied the effect of 3% and 6% 
hypertonic saline in viral bronchiolitis.  
The primary aim of their study was length of stay and the secondary 
outcome were need for supplemental oxygen and tube feeding. 
 The sample size was 292 but only 247 were completed the study. 
They were given 3%, 6% and 0.9% normal saline during hospital stay. 
They also added salbutamol for possible bronchoconstriction. The mean 
time for hospital stay was not altered in these three groups. AT the end of 
their study they have concluded that the hypertonic saline nebulization 
did not reduced the length of stay in the hospital
37
. 
Zhang l, Mendoza et al, conducted 11 randomized control trails 
including 1090 infants. They conducted 500 in patient’s trials,1 trail in 65 
out patients, 4 trails on 525 patients in emergency room. Totally 560 
patients received hypertonic saline. In these 560 patients, 503 patients 
received 3% hypertonic saline and 57 patients received 5% saline. 
 AT the end of the study they came to a conclusion that 
3%hypertonic saline significantly reduced the length of stay in infants 
admitted for bronchiolitis
2
. 
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Shawn Ralston et al, conducted a retrospective cohort study in 
which 444 doses of 3% hypertonic saline were administered to children 
less than 1 years of age. In these total doses 377 were given without 
bronchodilators. In the entire study only 4 adverse effects has occurred 
with 1%. By the end of the study they came to a conclusion that 3% 
hypertonic saline solution without adding bronchodilators had low 
adverse effect
38
.   
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STUDY JUSTIFICATION 
Most of acute wheezing episodes requiring hospitalization are 
caused by viruses. 
A therapy which maintains Airway hydration, promoting mucous 
clearance and reducing sub mucosal edema are required for reducing, 
admission rate, morbidity and length of stay. The studies which were 
done previously included children with bronchiolitis. There are no studies 
on Indian context, since seasonal variation is different from country to 
country. This study will be done in children between 2 to 6 years by 
excluding bronchiolitis.  In a country like India this therapy if proven will 
be cost effective and feasible. 
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OBJECTIVE OF THE STUDY 
To compare the efficacy of hypertonic saline versus normal saline 
as a vehicle for salbutamol Nebulization in acute wheezing attacks in 
children aged 2 to 6 years attending a tertiary care hospital.  
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METHODOLOGY 
1. STUDY DESIGN:-  
Clinical   trial  (Quasi experimental design). 
2. STUDY SETTING:- 
CASUALTY OF ―INSTITUTE OF CHILD 
HEALTH‖,  EGMORE, CHENNAI. 
3. STUDY PERIOD:- 
March 2014 to September 2014. 
4. TIMELINE:- 
DATA COLLECTION:-  March 2014 to July 2014. 
DATA ANALYSIS AND  
MANUSCRIPT PREPARATION:-} AUGUST 2014. 
SUBMISSION OF REPORT:- September 2014. 
5. STUDY POPULATION 
6. INCLUSION CRITERRIA:- 
  All children aged 2-6 years with acute wheezing 
attacks with clinical severity score of > 8. 
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EXCLUSION CRITERIA:- 
1. Children with cardiac disease. 
2. Children with chronic renal disease. 
3. Children requiring ICU admission. 
SAMPLE SIZE:- 
100. 
 SAMPLE SIZE CALCULATION:- 
Assuming an effect size of 0.25(from previous studies) with α error 
of 5% and power of 80% sample size of 50 in each group was arrived.  
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DEFINITIONS USED:- 
CASES:- 
 Children who received 3% hypertonic saline Nebulization along 
with salbutamol were called cases or treatment group. 
CONTROLS:- 
 Children who received 0.9% normal Saline Nebulization along 
with salbutamol. 
  
40 
 
ADMISSION CRITERIA:- 
Asthma clinical severity score of >6. 
PARAMETERS USED:- 
1. Respiratory rate. 
2. Auscultation. 
3. SPO2. 
4. Speech. 
5. Subcostal retractions. 
Each parameter scored as 1, 2, and 3. 
Total score categorized as 
1. Mild (5 to 7),  
2. Moderate (8 to 11),  
3. Severe (12 to 15). 
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OUTCOME MEASURED:- 
1. Admission rate 
2. Clinical severity score <6  after 3 doses of nebulization. 
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STUDY MANOUVERE 
The children were enrolled on the basis of inclusion criteria after 
obtaining written informed consent from either of parent. Base line 
demographic data and clinical history were noted in standard format. A 
baseline clinical severity score was obtained based on clinical 
examination at the start of the study. 
THE PROFORMA HAD THE FOLLOWING DATA:- 
1. Patient Name 
2. Age 
3. Sex 
4. OP Number 
5. Address 
6. History of Breathlessness 
7. History of chest retractions 
8. History of cyanosis 
9. History of noisy breathing 
10. History of refusal of feeds 
11. History of vomiting 
12. History of Immunization 
13. Socio economic status 
14. Past history of asthma 
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15. History of previous nebulization 
EXAMINATION 
  1.  Height 
  2. Weight 
  3. Sensorium 
4. Nutritional status 
5. Vitals 
6. Respiratory rate 
7.  Work of breathing 
8. Tracheal position  
9. Breath sounds  
10. Oxygen saturation 
11. Speech  
12. Examination of cardiovascular, abdomen and central nervous 
systems. 
Before starting of the study the children were examined by undressing of 
upper part of the body. The child’s attention was diverted so that clinical 
examinations can be done correctly. 
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Every alternate child was treated as control and cases. Each control was 
given 0.5 ml of salbutamol and 3.5 ml of normal saline nebulization with 
oxygen 3 times at 20 minutes intervals. Total volume of 4ml of liquid was 
used for nebulization. 
Each case was given 0.5ml of salbutamol and 3.5ml of hypertonic saline 
nebulization with oxygen three times at 20 minutes interval. 
 At the end of nebulization children in both groups were assessed on the 
basis of clinical severity score. Children with clinical severity score of 
more than 6 were admitted and with less than 6 were not admitted and 
treated as out patients. 
During the study 14 children were eliminated according to exclusion 
criteria. Out of 14 children 8 children had cardiac problems, 3 had renal 
problems and 3 children needed intensive care treatment. 
The results were enrolled in excel sheet and data was made for statistical 
analysis. Using SPSS software statistical data obtained. 
 
 
  
 
 
45 
 
DESCRIPTION OF VARIABLES:- 
1. Respiratory rate:- 
Respiratory rate was counted for a full one minute. Before counting 
respiratory rate child was kept in mothers lap in upright position to 
decrease anxiety. The clothes of upper part of the body were removed 
before counting respiratory rate. Using a watch with seconds hand 
respiratory rate was counted by inspection for a full 60 seconds. One 
chest rise and fall were counted as one breath. 
While counting respiratory rate attention of the child was diverted 
to prevent anxiety.  
2. Oxygen saturation:- 
Oxygen saturation was measured with a help of Nelcor pulse 
oximeter. Probe of the pulse oximeter was put over the child’s finger or 
toes which are not nail polished.  
3. Auscultation:- 
Before auscultation child’s clothes on the upper part of the body 
was removed and child was kept on mothers lap. Child’s attention was 
diverted and auscultated with the diaphragm of the stethoscope in all 
auscultatory areas (supraclavicular, infra clavicular, axillary, infra 
axillary, supra scapular, infra scapular, inter scapular areas) for 
adventitious sounds. 
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4. Speech:- 
Child was asked some questions and its speech pattern was noted. 
Whether child was able to speak in full sentence or in short sentence or in 
single words was noted.  
5. Work of breathing:- 
Work of breathing was noted by undressing the child’s upper part 
of the body and looking for intercostal, subcostal and supraclavicular 
retractions. 
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STATISTICAL ANALYSIS 
Data was entered in excel sheet. Statistical analysis was done using 
statistical software SPSS. Qualitative variables were expressed as 
proportion and quantitative variables as mean and standard deviation. 
Outcome variable was described as risk difference with 95% confidence 
interval. 
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ETHICAL CONSIDERATIONS 
 Ethical clearance from institutional review board was obtained. 
 Written informed consent was obtained from parent of each 
patient. 
 Strict confidentiality of data was maintained. 
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FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
Out of 114 children assessed 14 were eliminated (8 cardiac cases, 3 renal 
and 3 ICU admissions) and 100 cases were analyzed. 
  
Assessed for Eligibility 
(n=114) 
Excluded (n=14) 
Cardiac – 8 
Renal – 3 
ICU Admission - 3 
Selected 
n=100 
Treatment Group HS 
n=50 
Control group NS 
N=50 
Analyzed 
n=50 
Analyzed 
N=50 
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TABLE SHOWING FREQUENCY OF AGE IN STUDY 
POPULATION 
 
 
Age in years Frequency Percent 
2 8 8.00 
3 28 28.0 
4 45 45.0 
5 13 13.0 
6 6 6.0 
Total 100 100.0 
 
 
 
In this frequency table majority of the children were (45) in 4 years of 
age. 
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This bar diagram showing age frequency in study population   
Majority of the children were in 4 years of age group.  
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TABLE SHOWING FREQUENCY OF SEX 
DISTRIBUTION 
 
 
 
Sex Frequency Percent 
Male 61 61.0 
Female 39 39.0 
Total 100 100.0 
 
 
In this study 61% were males and 39% were females. 
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Sex
Female
Male
 
Pie chart showing frequency of sex distribution. 
 
  
 
 
 
Majority of population were (61%) males. 
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TABLE SHOWING H/O ASTHMA IN FAMILY 
 
 Family History of Asthma Frequency Percent 
 Present 50 50.0 
 Absent 
 
50 50.0 
 Total 100 100.0 
 
50% had family history of Asthma and 50% had none. 
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H/O Asthma In Family
No
Yes
Pie chart showing frequency of family history of Asthma in study 
population. 
50% had family history of Asthma
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FREQUENCY TABLE SHOWING HISTORY OF 
PREVIOUS NEBULIZATION IN STUDY GROUP 
 
H/O Previous 
Nebulization 
Frequency Percent 
 
Yes 
 
66 66.0 
 
No 
 
34 34.0 
Total 100 100.0 
 
66% had previous Nebulization and 34% had no history of previous 
Nebulization. 
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Pie chart showing frequency of previous nebulization in study 
population 
66% of children had previous history of nebulization 
 
 
H/O Previous Nebulisations
No
Yes
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Frequency table showing respiratory rate in study 
population 
 
Respiratory 
Rate/ min 
Frequency Percent 
31-35 9 9.0 
 
> 35 
 
91 91.0 
Total 100 100.0 
 
In this study majority (91%) of children had respiratory rate of > 35 
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Bar diagram showing frequency of respiratory rate in study 
population 
 
9% children had respiratory rate of between  31-35 and 91% had more 
than 35.  
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Frequency table showing work of breathing in study 
population 
 
Work of Breathing Frequency Percent 
 None 
 
3 3.0 
Intercostal / Sub sternal 
 
49 49.0 
Intercostal and 
supraclavicular 
 
48 48.0 
Total 100 100.0 
 
Out of 100 children 49 had inter costal or sub sternal retractions, 48 
had intercostal and supraclavicular retractions, 3 had none. 
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WOB
Intercos tel and supr
Intercos tal Substern
None
 
PIE CHART SHOWING FREQUENCY OF WORK OF 
BREATHING IN STUDY POPULATION 
  
Majority(49) of children had intercostal or sub sternal retractions.
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Frequency of breath Sounds in study population 
 
Breath Sounds Frequency Percent 
 Normal/End Expiratory 
wheezing 
 
2 2.0 
Expiratory wheezing 
 
10 10.0 
Inspiratory and Expiratory 
 
88 88.0 
Total 100 100.0 
 
88% of children had inspiratory & expiratory wheezing, 10% had 
expiratory wheezing and 2% had normal or end expiratory wheezing. 
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Bar diagram showing Breath Sounds in study population  
 
 
Majority of children (88%) had inspiratory and expiratory 
wheezing. 
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Frequency table showing oxygen saturation in study 
population 
 
SPO2 in % Frequency Percent 
 >95 
 
5 5.0 
 90-95 
 
95 95.0 
 Total 100 100.0 
 
 
Out of 100 children 95% had oxygen saturation of 90 to 95% and 5% had 
oxygen saturation of> 5%. 
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Pie chart showing frequency of oxygen saturation in study 
population 
 
Majority of children (95%) had oxygen saturation of 90 to95 % and 5% 
had more than 95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPO2 in %
90-95
> 95
66 
 
 
 Frequency table showing base line Score in study 
population 
 
 
Base line Score Frequency Percent 
 Moderate 19 19.0 
 Severe 81 81.0 
 Total 100 100.0 
 
81 % of children had severe base line score and 19 % had moderate 
base line score.  
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Pie chart showing distribution of base line score in study 
population 
 
 
Majority of children had severe base line score of 81%.  
Base line Score
Severe
Moderate
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Frequency showing Admission Rate in study population 
 
 
Admission Rate 
 
Frequency Percent 
 
Admitted 
 
70 70.0 
Not Admitted 
 
30 30.0 
Total 100 100.0 
 
 
Out of 100 children 70% were admitted and 30% were not admitted. 
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Pie chart showing frequency of admission rate in study population 
Majority of children (70%) were admitted in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Admission Rate
No
Yes
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Frequency table showing Clinical Severity Score in study 
population 
 
Clinical 
Severity Score Frequency Percent 
< 6 
 
32 32.0 
> 6 
 
68 68.0 
Total 100 100.0 
 
Majority (68%) of children had clinical severity score of >6. 
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Pie chart showing clinical severity score in study population 
 
 
Out of 100 children 68% had clinical severity score of > 6 and 32% had 
<6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Severity Score
> 6
< 6
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Adverse effects 
 Out of 100 children none of them had developed any adverse 
effects during the study. 
 
Speech 
 
All the children were able to speak in short sentences.
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Cross table showing Age group in years  
 
 Age 
group in 
years 
Saline 
Total 
 
P value 
 
 
 
Normal Hypertonic 
 
 
 
 
 
2-3 
 
 
No 
 
Percentage No  Percentage  
14 28% 22 44% 36 
 
 
 
 
 
 
 
 
0.096 
 
 
 
 
 
4-6 
 
 
 
 
 
36 
 
 
72% 
 
 
 
28 
 
 
56% 
 
 
 
64 
 
Total 
 
50 
  
50 
  
100 
 
P value is 0.096 and it is not significant, meaning that both groups are 
comparable in terms of age. 
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Bar diagram showing age group of children in this study. 
P value is 0.096 and it is not significant. 
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Cross table showing Sex ratio of children in this study 
 
  
 
 
 
Sex 
Saline 
Total 
 
P 
Value Normal Hypertonic 
No Percentage No Percentage 
  
Male 
 
28 
 
56 
 
33 
 
66 
 
61 
0.305 
       
  
 
Female 
 
22 
 
44 
 
17 
 
34 
 
39 
       
       
 
Total 
 
50 
  
50 
  
100 
      
       
 
The P value is 0.305 and it is not significant, meaning that sex ratio was 
comparable in both groups. 
  
  
76 
 
 
 
 
Bar diagram showing sex ratio in study population 
P value is 0.305. It is not significant. So both groups were 
comparable in terms of sex ratio. 
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Cross table showing H/O Asthma in Family in the study 
population 
 
  
 
 
H/O Asthma In 
Family 
Saline 
Total 
 
P 
Value 
Normal Hypertonic 
No Percentage No Percentage 
  
Yes 
 
20 
 
40 30 60 50 
0.046 
       
       
 No 30 60 20 40 50 
       
       
Total 50  50  100 
      
      
 
The P value is 0.046 and it is significant. 
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Bar diagram showing family history of asthma in the study 
population 
P value is 0.046 and it is significant.
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Cross table showing percentage of children with History of  
Previous Nebulization 
 
  
 
 
H/O Previous 
Nebulization 
Saline 
Total 
 
 
Normal Hypertonic 
P 
Value 
No Percentage No Percentage  
  
Yes 
 
36 
 
72 
 
30 
 
60 
 
66 
0.205 
       
       
  
 
No 
 
14 
 
28 
 
20 
 
40 
 
34 
       
       
Total 50  50  100 
      
       
 
P value is 0.205 and it is not significant, meaning that both groups 
were comparable in terms of History of Previous Nebulization. 
  
 
80 
 
 
Bar diagram showing History of Previous Nebulization in 
both groups 
P value is 0.205 and it is not significant. So both groups were 
comparable. 
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Cross table showing Respiratory Rate in study population 
  
 
 
Respiratory Rate 
 
Saline 
Total 
 
P 
Value 
Normal Hypertonic 
No Percentage No Percentage 
 31-35 1 2 8 16 9  
       
0.014 
       
 > 35 49 98 42 84 91 
       
       
Total 50  50  100 
      
       
 
P value is 0.014 and it is significant. 
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Bar diagram showing respiratory rate in this study 
population  
 
P value is 0.014 and it is significant.
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Cross table showing Work of Breathing in study population 
 
  
 
Work of 
Breathing 
Saline  
Total 
 
P 
Value 
Normal Hypertonic 
No Percentage No Percentage 
  
 
None 
 
1 
 
2 
 
2 
 
4 
 
3 
0.190 
       
       
  
Intercostal -
Sub sternal 
 
29 
 
58 
 
20 
 
40 
 
49 
       
       
  
Intercostal and 
supraclavicular 
 
20 
 
40 
 
28 
 
56 
 
48 
       
       
Total 50  50  100 
      
       
 
P value is 0.190 and it is not significant, meaning that both groups 
were comparable in terms of Work of Breathing. 
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Bar diagram showing Work of Breathing in study 
population 
 
P value is 0.190 and it is not significant. So both groups were comparable 
in terms of Work of Breathing.
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Cross table showing percentage of Breath Sounds in study 
population 
 
  
 
Breath Sounds 
 
Saline 
Total 
 
P 
Value 
Normal Hypertonic 
No Percentage No Percentage 
  
Normal/End 
Expiratory 
wheezing 
1 2 1 2 2 
0.445 
       
       
 Expiratory 
wheezing 
4 8 6 12 10 
       
       
 Inspiratory 
and 
Expiratory 
45 90 43 86 88 
       
       
Total 50  50  100 
      
       
 
P value is 0.445 and it is not significant, meaning that both groups 
were comparable. 
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Bar diagram showing Breath Sounds in study population  
 
P value is 0.445 and it is not significant, meaning that both groups were 
comparable in terms of Breath Sounds.
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Cross table showing percentage of children with Oxygen 
Saturation in this study population 
 
  
SPO2 in % 
 
Saline 
Total 
P 
Value Normal Hypertonic 
No Percentage No Percentage 
5 
0.169 
 > 95 4 8 1 2 
       
       
 90-95 46 92 49 98 95 
       
       
Total 50  50  100 
      
      
 
P value is 0.169 and it is not significant, meaning that both groups were 
comparable. 
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Bar diagram showing percentage of children with Oxygen 
Saturation in this study population. 
 
P value is 0.169 and it is not significant. So both groups were 
comparable.
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Cross table showing Base line Score in study population 
 
  
 
Base line Score 
 
Saline 
Total 
 
 
P 
Value 
Normal Hypertonic 
No Percentage No Percentage 
 Moderate 10 20 9 18 19 
0.799 
       
       
 Severe 40 80 41 82 81 
       
       
Total 50  50  100 
      
      
 
P value is 0.799 and it is not significant. So both groups were 
comparable. 
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Bar diagram showing Base line Score in this study 
population 
 
P value is 0.799 and it is not significant, meaning that both groups 
were comparable in terms of Base line Score.  
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PRIMARY OUTCOME 
Cross table showing Admission Rate in study population 
 
 
  
 
 
 Admission Rate 
 
Saline Total 
P 
Value 
Normal Hypertonic 
 
No Percentage No Percentage 
  
 
Admitted 
 
41 
 
82 
 
29 
 
58 
 
70 
.009 
       
       
  
Not 
Admitted 
 
9 
 
18 
 
21 
 
42 
 
30 
       
   
 
    
 
Total 
50  50  100 
      
      
 
P value is 0.009 and it is significant. 
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Bar diagram showing Admission Rate in study population 
 
P value is 0.009 and it is significant.Admission Rate
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Cross table showing Clinical Severity Score in study 
population 
 
  
 
 
 Clinical Severity 
Score 
 
Saline Total P 
Value 
Normal Hypertonic 
 
No Percentage No Percentage 
 < 6 10 20 22 44 32 
0.010 
       
       
 > 6 40 80 28 56 68 
       
 
 
 
Total 
 
 
 
50 
 
 
 
50 
 
 
 
100 
      
      
      
 
P value is 0.010 and it is significant. 
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Bar diagram showing Clinical Severity Score in study 
population 
 
P value is 0.010 and it is significant. 
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RESULTS 
Age:- 
 In our study children between 2 to 6 years were taken in to 
analysis. 8 children were in 2 years of age, 28 were in 3 years of age, 45 
children were in 4 years of age, 13 were in 5 years of age, and 6 were in 6 
years of age.  
Majority of children were in 4 years of age group with mean age of 
3.81(0.97). 
P value was 0.096 and it is not significant, so both groups were 
comparable in terms of age. 
Sex:- 
 In this study out of 100 children majority of the children were 
males 61%. 39% were females. In Normal saline group out of 50 children 
28 were males, 22 were females. 
 The P value was 0.305 and it is not significant. So both groups 
were comparable in terms of sex. 
History of Asthma in family:- 
 Out of 100 children analyzed 50% of the children had family 
history of Asthma. In Normal saline group 20 children had Family 
History of Asthma and 30 had no family History of Asthma. In 
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Hypertonic saline group 30 children had family History of Asthma and 20 
had no family History of Asthma.  
P value was 0.046 and it is significant. 
History of Previous Nebulization’s:- 
Out of 100 children analyzed 66% had previous history of 
Nebulization and 34% had no previous history of Nebulization. In normal 
saline group 72% of children had previous history of Nebulization and 
28% did not have previous history of Nebulization. IN hypertonic saline 
group 60 % had previous history of nebulization. 
P value was 0.205 and it is not significant meaning that both 
groups were comparable in terms of previous history of Nebulization. 
Respiratory Rate:- 
 Out of 100 children analyzed 9% of the children had Respiratory 
Rate  between   31 to 35 per minute. 91% had Respiratory Rate of more 
than 35 per minute. In normal saline group out of 50 children only one 
child had Respiratory Rate between 31 to 35 per minute. 49 children had 
Respiratory Rate of more than 35 per minute.  
 In Hypertonic saline group 8 children had Respiratory Rate 
between 31 to 35 per minute, 42 children had Respiratory Rate of more 
than 35 per minute.  
P value was 0.014 and it is significant. 
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Work of Breathing:- 
 Out of 100 children 3% of children had no retractions, 49% had 
intercostal / sub sternal retractions. 48% had intercostal and supra 
clavicular retractions.  
 In normal saline group 1 child had no retractions, 29 children had 
intercostal / sub sternal retractions and 20 children had intercostal / supra 
clavicular retractions. In hypertonic saline group 2 had no retractions , 20 
had inter costal or sub sternal retractions , 28 had inter costal and supra 
clavicular retractions. 
P value was 0.190 and it is not significant. So both groups were 
comparable in terms of Work of Breathing. 
Breath Sounds:- 
 Out of 100 children 2% had Normal or end Expiratory Wheezing. 
10% had Expiratory Wheezing, 88% had Inspiratory and expiratory 
wheezing. 
In normal saline group one child had normal or end expiratory 
wheezing, 4 had expiratory wheezing and 45 had inspiratory and 
expiratory wheezing. 
In hypertonic saline group one child had normal or end expiratory 
wheezing, 6 had expiratory wheezing, and 43 had inspiratory and 
expiratory wheezing. 
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P value was 0.445 and it is not significant, meaning that both 
groups were comparable in terms of breath sounds. 
SPEECH:     All children were able to speak in short sentences 
Oxygen saturation:- 
 Out of 100 children only 5% of children had oxygen saturation of 
more than 95%. 95% of children had oxygen saturation between 90 to 
95%. 
In normal saline group 4 children were had oxygen saturation of 
more than 95%. 46 children were had oxygen saturation between 90 to 
95%.  
In Hypertonic saline group 1 child had oxygen saturation of more 
than 95%. 49 children were had oxygen saturation between 90 to 95%. 
P value was 0.169 and it is not significant meaning that both 
groups were comparable in terms of oxygen saturation. 
Base line score:- 
 Out of 100 children none of them had mild Base line score. 19% of 
the children had moderate Base line score. 81% had severe Base line 
score. In normal saline group 10 children had moderate Base line score 
and 40 children had severe Base line score.  
In Hypertonic saline group 9 children had moderate Base line score 
and 41 children had severe Base line score. 
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P value was 0.799 and it is not significant meaning that both 
groups were comparable in terms of Base line score. 
Admission rate:- 
 Out of 100 children 70% were admitted and 30% were not 
admitted. In normal saline group 41(82%) children were admitted and 
9(18%) children were not admitted. 
In Hypertonic saline group 29(58%) children were admitted and 
21(42%) children were not admitted. 
P value was 0.009 and it is significant. So both groups were 
comparable in terms of admission rate. 
Risk difference:- 
 The admission rate in normal saline group was 82% and that in 
hypertonic saline was 58%. 
The Risk difference in admission rate was 24% with a 95 % 
confidence interval of 6 to 40%.  
Clinical severity score:- 
 Out of 100 children analyzed 32% of the children had clinical 
severity score of less than 6 and 68% had clinical severity score of more 
than 6. 
In normal saline group 10(20%) had clinical severity score of less 
than 6 and 40 children were had clinical severity score of more than 6.  
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In hypertonic saline group 22 children (44%) had clinical severity 
score of less than 6 and 28 children (56%) had clinical severity score of 
more than 6. 
P value was 0.010 and it is significant. 
Adverse effect:- 
 Out of 100 children none of them had any adverse effect. 
Hypertonic saline may cause bronchospasm but it depends upon the 
volume and the concentration of the saline used. 
When the concentration and volume of the saline increases there is 
more chance of bronchospasm. In this study less concentration (3%) and 
less volume (3.5ml) of saline was used along with a bronchodilator. so no 
adverse effects have been noted during the study. 
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DISCUSSION   
The study was done on 100 patients with 50 in Hyper tonic saline 
group and 50 in Normal saline group. 
 The mean (50) age was 3.81(0.97) with maximum patients (45%) 
of age 4. Sex ratio was 61:39 with male preponderance. Half of the 
patients had positive family history while 66% were nebulized in past. 
 91% had respiratory rate more than 35 while 9% had respiratory 
rate between31-35. 48% had intercostal and supraclavicular retractions 
while 49% had intercostal and sub sternal retractions and only 3% had no 
retractions. 88% had wheezing heard in both phases of respiration while 
10% had only expiratory wheezing and 2% had just end expiratory 
wheezing. 95% had oxygen saturation between 90 to 95% while only 5% 
had between above 95%. All of them were able to speak in short 
sentences. Overall as per baseline score 81% had severe respiratory 
distress and 19% had moderate respiratory distress. 
 Out of 100 patients, 70 were admitted, admission rate being 70%. 
Post nebulization clinical severity score was <6 in 32%. None of patients 
were noted to have any adverse events in either of group. 
 Both groups were comparable in terms of baseline parameters like 
ages sex, family history of asthma and previous history of nebulisations. 
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Normal saline group had more number of patients with respiratory rate 
>35 than the hypertonic saline group. But, other variables of scoring like 
work of breathing, oxygen saturation, auscultatory findings and speech 
were comparable in both the groups. The overall baseline clinical severity 
scoring was comparable in both treatment groups. 
 The admission rate in hypertonic saline group (58%) was less than 
that in normal saline group (82%) and the difference was statistically 
significant (p-0.009). The risk difference was 24% and its 95% 
confidence interval was (6 to 40%). 
 Post nebulization clinical severity score less than 6 was found in 
20% in normal saline group and 44% in hypertonic saline group which 
was also statistically significant (p=0.01). Thus more patients improved 
after hypertonic saline nebulization compared to normal saline 
nebulization. 
 Thus our study clearly indicates that hypertonic saline is superior 
to normal saline as a vehicle for salbutamol nebulization in preschool 
children with acute wheezing. 
 This is in concordance with study done by Dorit Ater et al which 
reported a 30% reduction in admission rate following hypertonic saline as 
compared to normal saline nebulization. 
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 Though hypertonic saline is not a mucolytic per se, it is capable of 
disintegrating ionic bonds within mucous gel and decreasing cross 
linkages and thus improves mucus clearance. Thus hypertonic saline is 
superior to normal saline in causing resolution of clinical symptoms. 
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LIMITATIONS 
 In our study, the respiratory rate in baseline clinical severity 
scoring was not comparable and had statistically significant difference 
between both treatment groups with severe patients in normal saline 
group. 
 However no such difference was observed in other variables of 
score as well as overall score making both the groups comparable. 
 Randomization was not done and alternate patients were allotted to 
either group. But this did not result in significant bias as most baseline 
parameters were comparable in both groups. 
 Blinding was not done which could have resulted in observer bias. 
 Past and present history of oral medications was not taken into 
considerations for analysis. This could have an effect on outcome 
measured. 
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RECOMMENDATIOINS 
 Hypertonic saline can be preferred over normal saline as a vehicle 
for salbutamol nebulization in preschool wheezing. 
 Further double blinded randomized control trial taking drug history 
into considerations to be done to prove the superiority of hypertonic 
saline over normal saline. 
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CONCLUSION 
 
 Hypertonic saline is superior to normal saline as a vehicle for 
salbutamol nebulization in decreasing admission rate and improving 
asthma severity score. 
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PROFORMA 
 
 
8. H/O NOISY BREATHING 1.YES                  2.NO 
 
DURATION 
9. H/O REFUSAL OF FEEDS 1.YES                   2.NO 
 
DURATION 
10. H/O VOMITING 1.YES                2.NO 
 
DURATION 
11. H/O IMMUNISATION 1.UPTO AGE     2.NOT UPTO AGE 
 
3.UNIMMUNISED   4.NOT KNOWN 
12. SOCIO ECONOMIC 
STATUS 
 
MODIFIED KUPPUSAMY 
SCALE 
 
 
PAST HISTORY 
 
13. H/O ASTHMA  
14. H/O PREVIOUS 
NEBULISATION 
 
15. H/O HOSPITALISATION  1.YES          2.NO 
 
 
 
 
1. 
 
PATIENT NAME 
 
SEX      1.MALE            2.FEMALE 
2. AGE DATE         MMYY 
3. OP NO; FATHERS  NAME   ; 
 
MOTHERS NAME;  
4. ADDRESS; 1.CHENNAI  CITY   2.OTHERS. 
5. H/O BREATHLESNESS 1.YES        2.NO 
 
DURATION 
6. H/O CHEST RETRACTIONS 1.YES      2.NO 
7. H/O  CYANOSIS 1.YES      2.NO 
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 EXAMINATION 
16. WEIGHT HEIGHT 
17. SENSORIUM 1.NORMAL 
 
2.ALTERED 
 
18. 
 
NUTRITIONAL 
STATUS 
 
 
19. 
 
VITALS 
 
PULSE                                   BP: 
 
20. 
 
RESPIRATORY 
RATE 
 
 
 
21. 
 
WORK OF 
BREATHING 
 
1.GRUNT      2.STRIDOR       
3.RETRACTIONS 
 
22. 
 
TRACHEAL 
POSITION 
 
1. MIDLINE  2.RIGHT .  3. LEFT. 
 
23. 
 
BREATH SOUNDS 
 
 
24. 
 
SPO2 
 
 
25. 
 
CVS 
 
 
26. 
 
ABDOMEN 
 
 
27. 
 
CNS 
 
28. Humidified Oxygen Administration                  1.Yes               2.No 
29. Nebulized 3% hypertonic saline with salbutamol            1.Yes      2.No 
(3 doses) 
30. Nebulized with0.9% saline with salbutamol                     1.Yes      2.No 
(3 Doses) 
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MASTER CHART- NORMAL SALINE GROUP 
S.N
O NAME 
A
G
E 
S
E
X 
OP 
NO 
BREATH
LESSNES
S 
CHEST 
RETRAC
TIONS 
CYAN
OSIS 
NOISY 
BREAT
HING 
H/O 
ASTH
MA 
IN 
FAMI
LY 
H/O 
PREVIOUS 
NEBULISA
TIONS 
SENSOR
IUM 
MUR
MUR 
RESPIR
ATIRY 
RATE 
W
OB 
BREA
TH 
SOU
NDS 
SP
O2 
SPEE
CH 
BASE
LINE 
SCOR
E 
OXY
GEN 
NEBULIS
ATION 
ADMIS
SION 
RATE 
 
CLINI
CAL 
SEVE
RITY 
SCOR
E 
ADVE
RSE 
EFFE
CTS 
1 SARANYA 4 2 1309 1 1 2 2 2 2 1 2 3 3 3 2 2 3 1 2 2 1 2 
3 KARPAGAM 4 2 1412 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
5 
MANIVANN
AN 4 1 1426 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
7 KANNAN 5 1 1482 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
9 VAISHNAVI 4 2 1582 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
11 MALAR 4 2 1108 1 1 2 2 2 1 1 2 3 2 3 1 2 2 1 2 1 2 2 
13 MANJULA 3 2 1110 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
15 MENAKA 4 2 1126 1 1 2 2 2 1 1 2 3 2 3 1 2 2 1 2 1 2 2 
17 SHERLYN 4 2 1232 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
19 
PADMAPRI
YA 4 2 1021 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
21 MONESH 2 1 1262 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
23 
JAYALAKS
HMI 4 2 1478 1 1 2 2 2 2 1 2 3 2 3 2 2 3 1 2 1 2 2 
25 LALITHA 4 2 1462 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 2 2 1 2 
27 
VENKATES
H 4 1 1724 1 1 2 2 2 1 1 2 2 2 3 2 2 3 1 2 1 2 2 
29 
NIRAJKUM
AR 4 1 1644 1 1 2 2 1 2 1 2 3 2 3 1 2 2 1 2 1 2 2 
31 DHILIP 4 1 1241 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
33 USHA 4 2 1538 1 1 2 2 2 2 1 2 3 2 2 2 2 2 1 2 1 2 2 
35 
YUVANRAJ
A 3 1 1432 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
37 VAISHALI 2 2 1892 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
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39 
SHAKTHIVE
L 5 1 2921 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 2 1 2 
41 SANTHOSH 5 1 1991 1 1 2 2 1 1 1 2 3 3 1 2 2 2 1 2 1 2 2 
43 
SHRAVANT
H 3 1 1758 1 1 2 2 2 1 1 2 3 2 2 2 2 2 1 2 1 2 2 
45 JAVID 6 1 1765 1 1 2 2 2 1 1 2 3 2 2 2 2 2 1 2 1 2 2 
47 LOGESH 6 1 1775 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
49 SOORYA 5 1 1781 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 2 1 2 
51 
THENNARA
SU 3 1 1785 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
53 AKASH 4 1 1795 1 1 2 2 2 1 1 2 3 1 3 2 2 2 1 2 1 2 2 
55 HARISHJAI 3 1 1789 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 2 1 1 2 
57 MARLIYA 5 2 1722 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 2 1 2 2 
59 ANUSIYA 4 2 1524 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 2 2 1 2 
61 
BALAMURA
LI 4 1 1695 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
63 
VELAMMA
L 4 2 1340 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 2 1 2 2 
65 RAJESH 4 1 1588 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 2 1 2 2 
67 JAISAIRAM 2 1 1694 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 2 2 1 2 
69 GOPINATH 6 1 1711 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
71 
BALAMURU
GAN 5 1 1710 1 1 2 2 1 2 1 2 3 2 3 2 2 3 1 2 2 1 2 
73 MADAVAN 3 1 1780 1 1 2 2 2 2 1 2 3 2 3 2 2 3 1 2 1 2 2 
75 BRINDHA 5 2 1790 1 1 2 2 1 2 1 2 3 2 3 2 2 3 1 2 1 2 2 
77 SHANTHI 4 2 1806 1 1 2 2 1 2 1 2 3 2 3 2 2 3 1 2 1 2 2 
79 
GURUCHAN
DIRAN 5 1 1012 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 2 1 2 2 
81 
KALAIARA
SI 3 2 1644 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 2 1 2 2 
83 GURU 2 1 1704 1 1 2 2 2 1 1 2 3 3 2 2 2 3 1 2 1 2 2 
85 PADMA 3 2 1723 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 2 1 2 2 
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87 DEVI 5 2 1401 1 1 2 2 1 2 1 2 3 2 3 2 2 3 1 2 1 2 2 
89 
ABDHULJA
FAR 4 1 1727 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 2 2 1 2 
91 VISHAL 3 1 1893 1 1 2 2 1 1 1 2 3 2 3 2 2 2 1 2 2 1 2 
93 POONGODI 4 2 1895 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
95 SOWMIYA 4 2 1897 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
97 VIJAYARUN 4 1 1988 1 1 2 2 2 1 1 2 3 2 3 1 2 2 1 2 1 2 2 
99 RAMU 3 1 1422 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 2 1 2 2 
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HYPERTONIC SALINE GROUP 
S
.
N
O NAME 
A
G
E 
S
E
X OP NO 
BREAT
HLESSN
ESS 
CHEST 
RETRAC
TIONS 
CYAN
OSIS 
NOISY 
BREAT
HING 
H/O 
ASTH
MA 
IN 
FAMI
LY 
H/O 
PREVIOUS 
NEBULISA
TIONS 
SENSOR
IUM 
MUR
MUR 
RESPIR
ATIRY 
RATE 
W
OB 
BREA
TH 
SOU
NDS 
SP
O2 
SPEE
CH 
BASE
LINE 
SCOR
E 
OXY
GEN 
NEBULIS
ATION 
ADMIS
SION 
RATE 
 
CLINI
CAL 
SEVE
RITY 
SCOR
E 
ADVE
RSE 
EFFE
CTS 
2 
MEENAKSH
I 4 2 1344 1 1 2 2 2 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
4 EASWARAN 3 1 2142 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
6 KASTURI 4 2 1304 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 1 1 2 2 
8 SHALINI 3 2 1342 1 1 2 2 1 1 1 2 2 2 3 2 2 2 1 1 1 2 2 
1
0 
NASEEMAB
ANU 4 2 972 1 1 2 2 1 1 1 2 3 2 2 2 2 2 1 1 2 1 2 
1
2 
NIJAMUDEE
N 6 1 1108 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
1
4 MANOHAR 5 1 1112 1 1 2 2 2 2 1 2 3 2 3 2 2 2 1 1 1 2 2 
1
6 KANNADAS 5 1 2194 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
1
8 
SETHUPAT
HI 4 1 1260 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 1 2 1 2 
2
0 PUSHPARAJ 3 1 962 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 1 2 1 2 
2
2 KRISHNA 3 1 1490 1 1 2 2 2 2 1 2 3 2 3 2 2 3 1 1 1 2 2 
2
4 JOSEPH 3 1 1714 1 1 2 2 2 2 1 2 3 2 3 2 2 3 1 1 1 2 2 
2
6 MUTHU 3 1 1625 1 1 2 2 2 1 1 2 3 2 2 2 2 2 1 1 1 2 2 
2
8 KAMARAJ 5 1 1633 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 1 1 2 2 
3
0 PADMARAJ 3 1 1242 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 2 1 2 
3
2 POORNIMA 3 2 1632 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 1 1 2 2 
3
4 MERLIN 4 2 1362 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
3
6 KALAIVANI 4 2 1898 1 1 2 2 2 1 1 2 3 3 3 2 2 3 1 1 2 1 2 
3
8 PRASANTH 3 1 1746 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 2 1 2 
4
0 VISHWA 2 1 1912 1 1 2 2 2 1 1 2 2 2 2 2 2 2 1 1 1 2 2 
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4
2 YOGESH 3 1 1999 1 1 2 2 2 1 1 2 2 3 3 2 2 3 1 1 1 2 2 
4
4 
JAISHAKTH
I 6 1 1770 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
4
6 
VARUNKU
MAR 5 1 1776 1 1 2 2 1 1 1 2 2 2 3 2 2 3 1 1 1 1 2 
4
8 GOMATHI 4 2 1782 1 1 2 2 2 1 1 2 2 3 2 2 2 3 1 1 2 1 2 
5
0 NARESH 3 1 1787 1 1 2 2 2 1 1 2 2 3 3 2 2 3 1 1 2 1 2 
5
2 SANTHOSH 4 1 1794 1 1 2 2 1 1 1 2 2 1 3 2 2 2 1 1 1 2 2 
5
4 VARSHINI 2 2 1690 1 1 2 2 1 2 1 2 2 2 2 2 2 2 1 1 1 2 2 
5
6 INIYAN 4 1 1701 1 1 2 2 2 2 1 2 3 2 3 2 2 3 1 1 1 2 2 
5
8 FATHIMA 3 2 1744 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
6
0 
SHANMUGA
M 3 1 1344 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
6
2 JOHNSON 4 1 1536 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 2 1 2 
6
4 
JANARDAN
AN 3 1 1592 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
6
6 
SRIRANGA
N 3 1 1596 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
6
8 YUVEDA 6 2 1697 1 1 2 2 1 2 1 2 3 1 3 2 2 2 1 1 1 2 2 
7
0 PUSHPA 4 2 1732 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 1 2 2 
7
2 
BHARANIK
UMAR 2 1 1824 1 1 2 2 2 2 1 2 3 2 1 2 2 2 1 1 1 2 2 
7
4 VASUKI 4 2 1444 1 1 2 2 1 1 1 2 3 3 2 2 2 3 1 1 1 2 2 
7
6 
VASANTHK
UMAR 3 1 1802 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 1 2 1 2 
7
8 
PANDIYAR
AJ 4 1 1784 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
8
0 KARTHICK 4 1 1764 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
8
2 
RAMACHA
NDIRAN 4 1 1622 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 1 2 2 
8
4 
SHAKTHIK
UMAR 4 1 1707 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
8
6 DHANUSH 4 1 1722 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
8
8 ANJALI 3 2 1726 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
9
0 ASHOK 4 1 1687 1 1 2 2 2 1 1 2 3 2 3 2 2 3 1 1 1 2 2 
9
2 ARUL 2 1 1729 1 1 2 2 1 1 1 2 3 3 3 2 2 3 1 1 2 1 2 
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9
4 JOSHNA 3 2 1892 1 1 2 2 2 2 1 2 3 3 3 1 2 3 1 1 1 2 2 
9
6 
POOVARAS
AN 4 1 1898 1 1 2 2 1 1 1 2 3 2 3 2 2 3 1 1 1 2 2 
9
8 
VIYAJARAN
I 4 2 1822 1 1 2 2 1 2 1 2 3 3 3 2 2 3 1 1 2 1 2 
1
0
0 
MANIMEGA
LAI 4 2 1894 1 1 2 2 1 2 1 2 3 2 3 2 2 3 1 1 1 2   
